C-reactive protein and peripheral artery disease among Japanese elderly: The Tsurugaya project

Hypertension Research

Volumn 27, Issue 12, 2004, Pages 955-961

  Hozawa, Atsushi ^a   Ohmori, Kaori ^a   Kuriyama, Shinichi ^a   Shimazu, Taichi ^a   Niu, Kaijun ^a   Watando, Aya ^a   Ebihara, Satoru ^a   Matsui, Toshifumi ^a   Ichiki, Masataka ^b   Nagatomi, Ryoichi ^a   Sasaki, Hidetada ^a   Tsuji, Ichiro ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Japan   (Japan)

Author keywords

Ankle brachial index; C reactive protein; Cardiovascular risk factors; Elderly; Japanese

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGED; ANKLE BRACHIAL INDEX; ARTERY DISEASE; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONFIDENCE INTERVAL; DIABETES MELLITUS; DRUG USE; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; JAPAN; MAJOR CLINICAL STUDY; MALE; SMOKING;

AGED; ANKLE; ARTERIOSCLEROSIS; ASIAN CONTINENTAL ANCESTRY GROUP; BRACHIAL ARTERY; C-REACTIVE PROTEIN; FEMALE; HUMANS; MALE; PERIPHERAL VASCULAR DISEASES; RISK FACTORS;

EID: 20144370683     PISSN: 09169636     EISSN: None     Source Type: Journal    
DOI: 10.1291/hypres.27.955     Document Type: Article

References (41)

1. Kuller LH, Tracy RP, Shaten J, Meilahn EN: Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study: Multiple Risk Factor Intervention Trial. Am J Epidemiol 1996; 144: 537-547.
2. Tracy RP, Lemaitre RN, Psaty BM, et al: Relationship of C-reactive protein to risk of cardiovascular disease in the elderly: results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol 1997; 17: 1121-1127.
3. Koenig W, Sund M, Frohlich M, et al: C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999; 99: 237-242.
4. Mendall MA, Strachan DP, Butland BK, et al: C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men. Eur Heart J 2000; 21: 1584-1590.
5. Ridker PM, Hennekens CH, Buring JE, Rifai N: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-843.
6. Danesh J, Whincup P, Walker M, et al: Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 2000; 321: 199-204.
7. Ridker PM, Rifai N, Clearfield M, et al, Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators: Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001; 344: 1959-1965.
8. Ridker PM, Stampfer MJ, Rifai N: Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein (a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001; 285: 2481-2485.
9. Albert CM, Ma J, Rifai N, Stampfer MJ, Ridker PM: Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation 2002; 105: 2595-2599.
10. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR: Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 47 1557-1565.
11. Pradhan AD, Manson JE, Rossouw JE, et al: Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. JAMA 2002; 288: 980-987.
12. Ridker PM: High-sensitivity C-reactive protein and cardiovascular risk: rationale for screening and primary prevention. Am J Cardiol 2003; 92: 17K-22K.
13. Ridker PM: Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003; 107: 363-369.
14. Danesh J, Wheeler JG, Hirschfield GM, et al: C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350: 1387-1397.
15. Vogt MT, Cauley JA, Newman AB, Kuller LH, Hulley SB: Decreased ankle/arm blood pressure index and mortality in elderly women. JAMA 1993; 270: 465-469.
16. Vogt MT, McKenna M, Anderson SJ, Wolfson SK, Kuller LH: The relationship between ankle-arm index and mortality in older men and women. J Am Geriatr Soc 1993; 41: 523-530.
17. Newman AB, Shemanski L, Manolio TA, et al: Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study: the Cardiovascular Health Study Group. Arterioscler Thromb Vasc Biol 1999; 19: 538-545.
18. Tsai AW, Folsom AR, Rosamond WD, Jones DW: Ankle-brachial index and 7-year ischemic stroke incidence: the ARIC study. Stroke 2001; 32: 1721-1724.
19. Abbott RD, Rodriguez BL, Petrovitch H, et al: Ankle-brachial blood pressure in elderly men and the risk of stroke: the Honolulu Heart Program. J Clin Epidemiol 2001; 54: 973-978.
20. Schroll M, Munck O: Estimation of peripheral arteriosclerotic disease by ankle blood pressure measurements in a population study of 60-year-old men and women. J Chron Dis 1981; 34: 261-269.
21. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH: Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 1998; 97: 425-428.
22. Van Der Meer IM, De Maat MP, Hak AE, et al: C-reactive protein predicts progression of atherosclerosis measured at various sites in the arterial tree: the Rotterdam Study. Stroke 2002; 33: 2750-2755.
23. Shinozaki T, Hasegawa T, Yano E: Ankle-arm index as an indicator of atherosclerosis: its application as a screening method. J Clin Epidemiol 1998; 51: 1263-1269.
24. Cui R, Iso H, Yamagishi K, et al: Ankle-arm blood pressure index and cardiovascular risk factors in elderly Japanese men. Hypertens Res 2003; 26: 377-382.
25. Ohmori K, Ebihara S, Kuriyama S, et al: The relationship between body mass index and a plasma lipid peroxidation biomarker in an older, healthy Asian community. Ann Epidemiol 2005; 15: 80-84.
26. Hozawa A, Ebihara S, Ohmori K, et al: Increased plasma 8-isoprostane levels in hypertensive subjects: the Tsurugaya Project. Hypertens Res 2004; 27: 557-561.
27. Imai Y, Satoh H, Nagai K, et al: Characteristics of a community based distribution of home blood pressure in Ohasma, a northern part of Japan. J Hypertens 1993; 11: 1441-1449.
28. Ledue TB, Weiner DL, Sipe JD, Poulin SE, Collins MF, Rifai N: Analytical evaluation of particle-enhanced immunonephelometric assays for C-reactive protein, serum amyloid A and mannose-binding protein in human serum. Ann Clin Biochem 1998; 35: 745-753.
29. Yamashina A, Tomiyama H, Takeda K, et al: Validity, reproducibility, and clinical significance of noninvasive brachial-ankle pulse wave velocity measurement. Hypertens Res 2002; 25: 359-364.
30. Ohnishi H, Saitoh S, Takagi S, et al: Pulse wave velocity as an indicator of atherosclerosis in impaired fasting glucose: the Tanno and Sobetsu study. Diabetes Care 2003; 26: 437-440.
31. Okamura T, Moriyama Y, Kadowaki T, Kanda H, Ueshima H: Non-invasive measurement of brachial-ankle pulse wave velocity is associated with serum C-reactive protein but not with α-tocopherol in Japanese middle-aged male workers. Hypertens Res 2004; 27: 173-180.
32. Chobanian AV, Bakris GL, Black HR, et al: The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-2571.
33. European Society of Hypertension-European Society of Cardiology Guidelines Committee: 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-1053.
34. Albert MA, Danielson E, Rifai N, Ridker PM, PRINCE Investigators: Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001; 286: 64-70.
35. Ridker PM, Rifai N, Lowenthal SP: Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 2001; 103: 1191-1193.
36. Yamada S, Gotoh T, Nakashima Y, et al: Distribution of serum C-reactive protein and its association with atherosclerotic risk factors in a Japanese population: Jichi Medical School Cohort Study. Am J Epidemiol 2001; 153: 1183-1190.
37. Albert MA, Glynn RJ, Ridker PM: Plasma concentration of C-reactive protein and the calculated Framingham Coronary Heart Disease Risk Score. Circulation 2003; 108: 161-165.
38. Hackam DG, Anand SS: Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence. JAMA 2003; 290: 932-940.
39. Meijer WT, Grobbee DE, Hunink MG, Hofman A, Hoes AW: Determinants of peripheral arterial disease in the elderly: the Rotterdam study. Arch Intern Med 2000; 160: 2934-2938.
40. Murabito JM, Evans JC, Nieto K, Larson MG, Levy D, Wilson PW: Prevalence and clinical correlates of peripheral arterial disease in the Framingham Offspring Study. Am Heart J 2002; 143: 961-965.
41. McDermott MM, Green D, Greenland P, et al: Relation of levels of hemostatic factors and inflammatory markers to the ankle brachial index. Am J Cardiol 2003; 92: 194-199.